What happens next in GLP-1 — and when.

Get the briefing

What moved in the GLP‑1 field, in your inbox.

@glp1briefing

Indications › Diabetes (unspecified)

GLP‑1 drugs in diabetes (unspecified)

Which incretin agents are being studied in diabetes (unspecified), by whom, and when each trial is due to report. Conditions are grouped from the registry’s own wording, which records the same disease several ways.

Trials on file
131
Active
14
Results scheduled
8
Molecules studied
8
Sponsors
41

No GLP‑1 or incretin drug is FDA-approved for diabetes (unspecified). The trials below are studies, not approvals, and most drugs tested in a new condition never get approved for it.

No GLP-1 or incretin drug is approved for diabetes (unspecified), so everything below is investigational. Most drugs tested in a new condition never reach approval for it, and a registration is not evidence of benefit. 106 of the 131 trials on file are phase 3 or later — the stage sized for a regulator to act on, against 25 still in early phases. 41 distinct sponsors are involved, 97 of the trials run commercially and the rest by universities and hospitals.

Molecules studied in this indication

albiglutide · danuglipron · dulaglutide · exenatide in this indication · liraglutide in this indication · lixisenatide · semaglutide in this indication · tirzepatide

Results due in this indication

Est. completionDrugTrialPhaseParticipants
2026-12-31semaglutideAssessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)
NCT06959784 · China-Japan Friendship Hospital
P4142
2027-07semaglutideGlucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis
NCT07017270 · Unity Health Toronto
P4100
2027-12semaglutideSemaglutide Treatment for Hyperglycaemia After Renal Transplantation
NCT05702931 · Rigshospitalet, Denmark
P4104
2027-12-15tirzepatideNormal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide
NCT06657209 · Stanford University
P4104
2028-02-09lixisenatideEvaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes
NCT07117240 · Medical University of Warsaw
P4100
2028-06semaglutideSemaglutide Treatment in Type 1 Diabetes
NCT06909006 · Nordsjaellands Hospital
P3122
2028-07semaglutideImpact GLP-1 Agonists Following Bariatric
NCT06132477 · University of Missouri-Columbia
P4150
2028-12-31semaglutideNew Triple Therapy in Newly Diagnosed Type 2 Diabetes
NCT06946628 · Sun Yat-sen University
P3296

Trials on file

All 131 incretin trials recorded in this indication, active first.

DrugTrialStatusPhaseParticipants
semaglutideNew Triple Therapy in Newly Diagnosed Type 2 Diabetes
NCT06946628 · Sun Yat-sen University
Not yet recruitingP3296
tirzepatideNew Triple Combination Therapy in Newly Diagnosed Type 2 Diabetes
NCT07635953 · Sun Yat-sen University
Not yet recruitingP3296
semaglutideImpact GLP-1 Agonists Following Bariatric
NCT06132477 · University of Missouri-Columbia
RecruitingP4150
semaglutideAssessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)
NCT06959784 · China-Japan Friendship Hospital
Enrolling by invitationP4142
semaglutideSemaglutide Treatment in Type 1 Diabetes
NCT06909006 · Nordsjaellands Hospital
Not yet recruitingP3122
semaglutideSemaglutide Treatment for Hyperglycaemia After Renal Transplantation
NCT05702931 · Rigshospitalet, Denmark
RecruitingP4104
tirzepatideNormal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide
NCT06657209 · Stanford University
RecruitingP4104
semaglutideGlucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis
NCT07017270 · Unity Health Toronto
RecruitingP4100
lixisenatideEvaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes
NCT07117240 · Medical University of Warsaw
Enrolling by invitationP4100
semaglutideSemaglutide 2.4 mg in Patients With Poor Weight-loss
NCT05073835 · University College, London
Active, not recruitingP370
tirzepatideTirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV
NCT07707778 · National Taiwan University Clinical Trial Center
Enrolling by invitationP460
semaglutideSemaglutide vs Sitagliptin
NCT05195944 · University Health Network, Toronto
Enrolling by invitationP458
dulaglutideGLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
NCT04731272 · University of Pennsylvania
RecruitingP230
semaglutideAlleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide
NCT06387199 · McGill University Health Centre/Research Institute of the McGill University Health Centre
RecruitingP2/P326
albiglutideEffect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
NCT02465515 · GlaxoSmithKline
CompletedP49,463
liraglutideLiraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
NCT01179048 · Novo Nordisk A/S
CompletedP39,341
semaglutideTrial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
NCT01720446 · Novo Nordisk A/S
CompletedP33,297
semaglutideA Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
NCT02692716 · Novo Nordisk A/S
CompletedP33,183
liraglutideEfficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes
NCT02730377 · Novo Nordisk A/S
CompletedP41,991
semaglutideEfficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
NCT02607865 · Novo Nordisk A/S
CompletedP31,864
liraglutideDual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
NCT01336023 · Novo Nordisk A/S
CompletedP31,663
liraglutideThe Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
NCT01836523 · Novo Nordisk A/S
CompletedP31,398
semaglutideEfficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes
NCT01930188 · Novo Nordisk A/S
CompletedP31,231
semaglutideEfficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.
NCT02648204 · Novo Nordisk A/S
CompletedP31,201
liraglutideTo Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together
NCT00318461 · Novo Nordisk A/S
CompletedP31,091
semaglutideEfficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes
NCT02128932 · Novo Nordisk A/S
CompletedP31,089
liraglutideEffect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
NCT00318422 · Novo Nordisk A/S
CompletedP31,041
liraglutideA 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus
NCT02501161 · Novo Nordisk A/S
CompletedP31,012
liraglutideThe Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes
NCT00856986 · Novo Nordisk A/S
CompletedP3987
liraglutideEffect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes
NCT00614120 · Novo Nordisk A/S
CompletedP3929
semaglutideTrial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity
NCT05579977 · Pfizer
TerminatedP2902
semaglutideEfficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
NCT03061214 · Novo Nordisk A/S
CompletedP3868
liraglutideThe Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
NCT02098395 · Novo Nordisk A/S
CompletedP3835
semaglutideEfficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
NCT02863328 · Novo Nordisk A/S
CompletedP3822
liraglutideA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.
NCT02607306 · Novo Nordisk A/S
CompletedP3819
semaglutideEfficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes
NCT01885208 · Novo Nordisk A/S
CompletedP3813
semaglutideEfficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
NCT03136484 · Novo Nordisk A/S
CompletedP3788
liraglutideTo Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c
NCT00294723 · Novo Nordisk A/S
TerminatedP3746
semaglutideEfficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin
NCT03021187 · Novo Nordisk A/S
CompletedP3731
liraglutideA Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)
NCT03172494 · Novo Nordisk A/S
CompletedP3720
semaglutideEfficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
NCT02863419 · Novo Nordisk A/S
CompletedP3711
semaglutideDose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
NCT02461589 · Novo Nordisk A/S
CompletedP2706
semaglutideEfficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only
NCT02906930 · Novo Nordisk A/S
CompletedP3703
exenatidePhase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
NCT02229396 · AstraZeneca
CompletedP3695
liraglutideThe Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus
NCT00700817 · Novo Nordisk A/S
CompletedP3665
liraglutideA Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.
NCT02505334 · Novo Nordisk A/S
CompletedP3635
semaglutideMultiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
NCT01923181 · Novo Nordisk A/S
CompletedP2632
semaglutideA Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes
NCT02207374 · Novo Nordisk A/S
CompletedP3601
dulaglutideA Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes
NCT04809220 · Eli Lilly and Company
CompletedP3591
liraglutideEffect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
NCT00331851 · Novo Nordisk A/S
CompletedP3584
semaglutideResearch Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes
NCT03191396 · Novo Nordisk A/S
CompletedP3577
liraglutideEffect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
NCT00333151 · Novo Nordisk A/S
CompletedP3576
liraglutideA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus
NCT01952145 · Novo Nordisk A/S
CompletedP3557
liraglutideA Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus
NCT02420262 · Novo Nordisk A/S
CompletedP3506
semaglutideEfficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.
NCT02849080 · Novo Nordisk A/S
CompletedP3504
liraglutideEffect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes
NCT00518882 · Novo Nordisk A/S
CompletedP3467
exenatidePhase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
NCT02229383 · AstraZeneca
CompletedP3464
semaglutideSafety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes
NCT03015220 · Novo Nordisk A/S
CompletedP3458
liraglutideA Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)
NCT03175120 · Novo Nordisk A/S
CompletedP3453
liraglutideThe Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes
NCT01617434 · Novo Nordisk A/S
CompletedP3451